ErbB2/Her2 anticorps

N° du produit ABIN2688859

Détail du produit anti-ErbB2/Her2 anticorps

Antigène: ErbB2/Her2 (Receptor tyrosine-protein kinase erbB-2 (ErbB2/Her2))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp ErbB2/Her2 est non-conjugé

Application: Flow Cytometry (FACS), Immunoprecipitation (IP), Immunohistochemistry (Formalin-fixed Sections) (IHC (f)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Marque: BD Pharmingen™

Attributs du produit: C-erbB-2 (also known as HER2/neu), a 185 kDa transmembrane glycoprotein, is a member of the type 1 growth factor receptor subfamily which also includes c-erbB-3, c-erbB-4 and the epidermal growth factor receptor (EGFR) (also known as c-erbB-1). Members of this receptor subfamily mediate the proliferation and differentiation of normal cells. They have a common structure consisting of an extracellular domain, a transmembrane region, and a cytoplasmic sequence. The extracellular regions contain two cysteine-rich domains, and the intracellular regions have sequence homology to known tyrosine kinases. C-erbB-3 reactivity has been detected in proximal kidney tubules, mucosal epithelium in the gastointenstinal tract, and squamous epithelium in skin. Most other normal adult tissue show little or no reactivity with antibodies against c-erbB-2, including breast, ovary, spleen, liver, bone marrow, prostate, adrenal, and lung. However, c-erbB-2 is overexpressed in many human breast, stomach, ovary and bladder carcinomas. EGFR, c-erbB-3 and c-erbB-4 are also overexpressed in various human tumor cells, and it is thought that aberrant activation of type 1 growth factor kinase activities may contribute to tumor progression.

BD Pharmingen™ Purified Mouse Anti-Human c-erbB-2 - Purified - Clone 9G6 - Isotype Mouse IgG1 - Reactivity Hu - 100 μg

Purification: The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Immunogène: Recombinant human c-erbB-2

Clone: 9G6

Isotype: IgG1

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Concentration: 0.5 mg/mL

Buffer: Aqueous buffered solution containing ≤0.09 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C

Stockage commentaire: Store undiluted at 4°C.

Références pour anticorps anti-ErbB2/Her2 (ABIN2688859)

Stål, Sullivan, Sun, Wingren, Nordenskjöld: "Simultaneous analysis of c-erbB-2 expression and DNA content in breast cancer using flow cytometry." dans: Cytometry, Vol. 16, Issue 2, pp. 160-8, (1994) (PubMed).

Carraway, Cantley: "A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling." dans: Cell, Vol. 78, Issue 1, pp. 5-8, (1994) (PubMed).

Penault-Llorca, Adelaïde, Houvenaeghel, Hassoun, Birnbaum, Jacquemier: "Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation." dans: The Journal of pathology, Vol. 173, Issue 1, pp. 65-75, (1994) (PubMed).

Schwechheimer, Läufle, Schmahl, Knödlseder, Fischer, Höfler: "Expression of neu/c-erbB-2 in human brain tumors." dans: Human pathology, Vol. 25, Issue 8, pp. 772-80, (1994) (PubMed).

Rubin, Finstad, Wong, Almadrones, Plante, Lloyd: "Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis." dans: American journal of obstetrics and gynecology, Vol. 168, Issue 1 Pt 1, pp. 162-9, (1993) (PubMed).

Singleton, Niehans, Gu, Litz, Hagen, Qiu, Kiang, Strickler: "Detection of c-erbB-2 activation in paraffin-embedded tissue by immunohistochemistry." dans: Human pathology, Vol. 23, Issue 10, pp. 1141-50, (1992) (PubMed).

van de Vijver, Peterse, Mooi, Wisman, Lomans, Dalesio, Nusse: "Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer." dans: The New England journal of medicine, Vol. 319, Issue 19, pp. 1239-45, (1988) (PubMed).

Détails sur ErbB2/Her2

Antigène: ErbB2/Her2 (Receptor tyrosine-protein kinase erbB-2 (ErbB2/Her2))

Autre désignation: C-ErbB-2 (ErbB2/Her2 Produits)

Synonymes: anticorps CD340, anticorps HER-2, anticorps HER-2/neu, anticorps HER2, anticorps MLN 19, anticorps NEU, anticorps NGL, anticorps TKR1, anticorps Erbb-2, anticorps Neu, anticorps c-erbB2, anticorps c-neu, anticorps mKIAA3023, anticorps wu:fv70f10, anticorps zgc:63601, anticorps erb2, anticorps erb-b2 receptor tyrosine kinase 2, anticorps ERBB2, anticorps Erbb2, anticorps erbb2

Pathways: Signalisation RTK, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Skeletal Muscle Fiber Development